| |
|
Open Monoclonal Technology, Inc. ("OMT")
OMT is a private biotechnology company with a new, fully human monoclonal antibody (mAb) platform based on transgenic rats. Antibodies are an important class of pharmaceutical products due to breakthroughs that have made them more human-like and eliminated unwanted side effects. The rat is a widely used laboratory animal with a well characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies.
Previously, genetically engineered mice were the only animals used as human antibody platforms. The mouse is expensive to license and has restricted development options. With antibody sales expected to exceed $50 billion by 2013, there is an opportunity for OMT and its new antibody platform with unrestricted development options.
OMT's founder, Dr. Roland Buelow, has more than twenty years of experience in the biotechnology field and is the inventor of numerous patents. He was a founder of THP Inc., which developed genetically engineered rabbits expressing human antibodies and was acquired by Roche in 2007.
OMT's antibody platform has freedom to operate and broad patent protection. |
|
| |
|
|
|
